Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Harvesting specific plant metabolites from hairy root cultures using magnetized n

    SBC: NAPROGENIX, INC.            Topic: NCCIH

    DESCRIPTION: Plants produce a wide variety of valuable bioactive metabolites, but these are commonly present in low concentrations in the wild-type plant. This makes the separation and purification of these compounds complicated and expensive. The applicant company, Naprogenix Inc, has developed a technology for increasing the yields of specific bioactive metabolites in mutant plant cell cultures ...

    STTR Phase I 2014 Department of Health and Human Services
  2. Orally available transition state inhibitors for triple negative breast cancer

    SBC: Nanometics LLC            Topic: NCI

    Problem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the ...

    STTR Phase I 2014 Department of Health and Human Services
  3. Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer


    DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...

    STTR Phase I 2014 Department of Health and Human Services
  4. Modified RNA tools and diagnostics for drug abuse


    DESCRIPTION (provided by applicant): Project Summary/Abstract RNA modifications are numerous, and range from simple methylation to complex changes such as addition of aminoacylcarbamoyl moieties. These modifications and, the levels at which are present, are emerging as important regulators of biological processes, and perturbations such as chemical or drug exposure can alter the patterns of specif ...

    STTR Phase I 2014 Department of Health and Human Services
  5. Mitochondrial Uncoupling as a Therapeutic Target in Obesity

    SBC: Nano-Mite Technologies, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Obesity is recognized as a national and global epidemic, as approximately 65% of adults in the United States are classified as overweight or obese as defined by body mass index (BMI). In fact, in the year 2000, the human race reached a historical landmark, when for the first time in history the number of adults with excess weight surpassed the number of those w ...

    STTR Phase I 2014 Department of Health and Human Services
  6. Hand Rehabilitation using Variable Assistance through Force and EMG Feedback


    DESCRIPTION (provided by applicant): This project proposes to develop and evaluate a hand rehabilitation system for chronic hemiparetic stroke survivors that have lost their ability to full control their hand. Stroke is the leading cause of adult disability, and is the third leading cause of death in the United States. Stroke survivors often face a significant loss of functional motor control in ...

    STTR Phase I 2014 Department of Health and Human Services
  7. Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat


    DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...

    STTR Phase I 2014 Department of Health and Human Services
  8. Exosomal drug formulations

    SBC: 3P BIOTECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): More people in the U.S. (160,340 per year) die of lung cancer than of prostate, breast, and colon cancer combined. The most common type of lung cancer, non-small-cell lung cancer (NSCLC), accounts for 75% of all lung cancers. Regrettably, 85% of all patients diagnosed with NSCLC eventually die of the disease within 5 years, due to micro-metastasis and relapse. ...

    STTR Phase I 2014 Department of Health and Human Services
  9. Prevention of erectile dysfunction following prostate cancer radiotherapy

    SBC: Humanetics Corporation            Topic: NCI

    DESCRIPTION (provided by applicant): The aim of this proposal is to evaluate BIO 300 as an effective therapy to prevent and/or mitigate the erectile dysfunction (ED) that is commonly observed following radiotherapy (RT) for prostate cancer. Prostate cancer is the most common cancer among men in the United States. Approximately half of prostate cancer patients will undergo RT as a part of thei ...

    STTR Phase I 2014 Department of Health and Human Services
  10. Science Take-Out Kits for Environmental Health Education

    SBC: Science Take-Out, LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Nearly percent of death and disease worldwide is linked to environmental factors WHO therefore it is critical that the general public has basic understanding of how the environment affects their health and how they might protect themselves against environmental exposures Unfortunately environmental health content is typically covered on a very ...

    STTR Phase I 2014 Department of Health and Human Services
US Flag An Official Website of the United States Government